Rigenerand Srl, a Medolla (MO), Italy-based company committed to develop biomedical devices supporting the culture of stem cells for pre-clinical and clinical applications, raised €8.7m in venture capital funding.
Milan, Italy-based vc firm Principia SGR made the investment via Principia III – Healthcare.
The company intends to use the funds to invest in technology and realize a new “cell factory”.
Founded in 2009 by Prof. Massimo Dominici and Prof. Pierfranco Conte, as a spin-off resulting from a joint venture between biomedical company RanD and researchers from the University of Modena and Reggio Emilia, Rigenerand owns proprietary technology to develop and produce biomedical tools to empower the ex-vivo phase of stem cells expansion combining the need of high cell yield with innovative biocompatible materials.
The company, led by CEO Giorgio Mari, is now advancing two different projects.